I would point to two elements in particular that are significant. South Africa is already a regional leader in vaccine production. They have outstanding manufacturing capacity and have been working on producing generic vaccines, but there has been no mRNA vaccine production capacity in sub-Saharan Africa or in Africa more generally. This is the first WHO-backed initiative to ensure that there is African production of mRNA vaccine primarily aiming for African consumption.
The second point is that this will be a hub that will have a number of spokes across the continent where additional production will happen. This is where the core of the technology transfer and the scale-up of capability will occur. That will then be reproduced in other production facilities, so we'll get a much bigger bang for this investment than we would have by investing in competing, discrete initiatives.
We're very excited. The South Africans are very excited and, frankly, so are other stakeholders across the African continent.